ストックスクリーナーアプリを入手
38.42
1.06%
-0.41
アフターアワーズ：
38.42
Novo Nordisk Adr (NVO) 最新ニュース
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. - The Motley Fool
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher - The Motley Fool
Novo Nordisk and Eli Lilly Just Got Some Fantastic News - The Motley Fool
Novo Nordisk A/S Tokenized Stock (Coinbase) Price Today - CryptoRank
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Novo Nordisk A/S : UBS remains Neutral - marketscreener.com
Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback - Yahoo Finance
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now? - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum - Zacks Investment Research
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Zacks Investment Research
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Yahoo Finance
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Zacks Investment Research
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Yahoo Finance
Novo Nordisk A/S: Dividend historical data and projections - marketscreener.com
GLP-1 weight-loss drugs slow biological aging, recent studies show - NewsNation
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme - TipRanks
Buybacks total 37.8M B shares at Novo Nordisk (NVO), under a programme capped at DKK 15B. - Stock Titan
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. - The Motley Fool
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
4 Healthcare Stocks Worth Owning for the Next Decade - The Motley Fool
Novo Nordisk price target lowered to $40 from $47 at BMO Capital - TipRanks
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $40 - Moomoo
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
Novo Nordisk A/Sshare repurchase programme - The Manila Times
Novo Nordisk A/Sshare repurchase programme - GlobeNewswire
Novo Nordisk A/Sshare repurchase programme - Yahoo Finance
Novo Nordisk A/S (NVO) Stock Forecast and Price Target 2026 $NVO - MarketBeat
Weekly Recap: Large B-share buyback and GLOBE pricing deal participation - TradingView
Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh Actuals & Estimates (SET:NOVOB80) - TradingView
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze - The Motley Fool
Novo Nordisk A/S (NVO) Options Chain - Yahoo! Finance Canada
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Globe and Mail
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth - Yahoo Finance
Novo Nordisk loses another patent behind Ozempic and Wegovy drugs - JUVE Patent
Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land - Yahoo Finance
Novo Nordisk A/S (NVO) Stock Forecasts - Yahoo Finance
Novo Nordisk stock target cut at Citi on lack of margin growth - Yahoo Finance
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Novo Nordisk A/S (NOV.DU) recent insider transactions - Yahoo Finance UK
Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’ - Barchart.com
0.47%
大文字化:
|
ボリューム (24 時間):